AbbVie to Buy Apogee Therapeutics for $10.9 Billion
AbbVie agreed to acquire Apogee Therapeutics for $10.9 billion, adding experimental treatments for atopic dermatitis to its dermatology pipeline.
AbbVie has agreed to acquire Apogee Therapeutics for $10.9 billion, a deal that bolsters the pharmaceutical giant's presence in dermatology with a pipeline of experimental treatments for atopic dermatitis, commonly known as eczema.
The acquisition, announced on Monday, gives AbbVie access to Apogee's lead candidate, an antibody targeting OX40L, which is in mid-stage trials for moderate-to-severe atopic dermatitis. The deal also includes earlier-stage programs for asthma and chronic obstructive pulmonary disease. AbbVie will pay $75 per share in cash, a 58% premium to Apogee's closing price on Friday.
For interest rate and central bank policy traders, the transaction is notable for its size and the premium paid, which may signal confidence in the biotech sector's growth prospects. Such large M&A deals can influence risk sentiment and capital flows, potentially affecting bond yields and currency markets. Traders can monitor the impact on AbbVie's stock and broader market indices on NowPrice's live rates dashboard.
Looking ahead, investors will watch for regulatory approvals and the progress of Apogee's clinical trials. The deal is expected to close in the third quarter of 2026. Additionally, the broader biotech M&A landscape may see increased activity as large pharmaceutical companies seek to bolster pipelines ahead of patent expirations.